Brazil: Fiocruz Releases a Public Call for the Selection of Private Companies Interested in Product Development Partnerships (PDPs) for Pembrolizumab and a Herpes Zoster Vaccine
26/10/2026
The Oswaldo Cruz Foundation – Fiocruz, through its Immunobiological Technology Institute (Bio-Manguinhos), has issued Public Call No. 002/2026 to select private entities interested in Productive Development Partnerships (PDPs).
The technologies covered are listed in Annex I of the Public Call Notice: the biopharmaceutical Pembrolizumab and the Herpes Zoster vaccine.
Proposals must comply with the requirements and conditions set forth in the notice and its annexes and be submitted by November 4, 2026.
Souto Correa’s Life Sciences & Healthcare team continues to monitor developments related to the public call and remains available to provide further information.
